Published in J Urol on September 01, 2000
Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer (2003) 1.98
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol (2011) 1.71
Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem (2002) 1.60
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res (2006) 1.50
Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer (2004) 1.44
Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model. Mediators Inflamm (2011) 1.42
Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem (2001) 1.36
Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer (2006) 1.32
Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis (2003) 1.31
Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol (2005) 1.26
COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer (2007) 1.11
Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA. Mol Cancer (2003) 1.11
Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia (2001) 1.08
Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc Natl Acad Sci U S A (2002) 1.07
COX-2 and cancer: a new approach to an old problem. Br J Pharmacol (2001) 1.02
Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomarkers Prev (2010) 1.01
Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine. Neoplasia (2007) 1.01
Cytosolic phospholipase A2-alpha: a potential therapeutic target for prostate cancer. Clin Cancer Res (2008) 1.01
Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metastasis (2002) 1.01
Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer (2009) 0.99
The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. BMC Cancer (2006) 0.97
Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br J Cancer (2012) 0.96
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis (2002) 0.93
Involvement of COX-2/PGE2 signalling in hypoxia-induced angiogenic response in endothelial cells. J Cell Mol Med (2012) 0.92
Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer (2006) 0.92
Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases. Cancer Metastasis Rev (2014) 0.92
Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer. J Nutrigenet Nutrigenomics (2009) 0.88
Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer. BMC Cancer (2006) 0.87
Upregulation of androgen-responsive genes and transforming growth factor-β1 cascade genes in a rat model of non-bacterial prostatic inflammation. Prostate (2013) 0.85
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. Br J Cancer (2007) 0.84
COX-2 expression and tumor angiogenesis in colorectal cancer. World J Gastroenterol (2004) 0.84
In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog. PLoS One (2012) 0.83
Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors? Br J Cancer (2003) 0.83
The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer. Biologics (2008) 0.82
Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Mol Cancer Ther (2008) 0.82
Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line. Pharm Res (2003) 0.81
Antibiotic and anti-inflammatory use and the risk of prostate cancer. BMC Res Notes (2009) 0.81
The expression of COX-2 in VEGF-treated endothelial cells is mediated through protein tyrosine kinase. Mediators Inflamm (2002) 0.81
Blood level omega-3 Fatty acids as risk determinant molecular biomarker for prostate cancer. Prostate Cancer (2013) 0.80
Cytotoxic necrotizing factor from Escherichia coli induces RhoA-dependent expression of the cyclooxygenase-2 Gene. Infect Immun (2001) 0.80
Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo. Strahlenther Onkol (2010) 0.79
The inhibitory effect of a novel polypeptide fraction from Arca subcrenata on cancer-related inflammation in human cervical cancer HeLa cells. ScientificWorldJournal (2014) 0.78
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer. Invest New Drugs (2016) 0.76
Roles of Eicosanoids in Prostate Cancer. Future Lipidol (2008) 0.75
Diabetic macular edema, retinopathy and age-related macular degeneration as inflammatory conditions. Arch Med Sci (2016) 0.75
2-[4-(Methyl-sulfon-yl)phen-yl]acetonitrile. Acta Crystallogr Sect E Struct Rep Online (2011) 0.75
Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer. Pharmaceuticals (Basel) (2010) 0.75
Do Aspirin and Other NSAIDs Confer a Survival Benefit in Men Diagnosed with Prostate Cancer? A Pooled Analysis of NIH-AARP and PLCO Cohorts. Cancer Prev Res (Phila) (2017) 0.75
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet (1999) 6.69
Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science (1999) 6.37
Guided medication dosing for inpatients with renal insufficiency. JAMA (2001) 6.25
Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol (1999) 5.83
Facial fractures and submental tracheal intubation. Anaesthesia (2002) 4.13
The Australian Incident Monitoring Study. Crisis management--validation of an algorithm by analysis of 2000 incident reports. Anaesth Intensive Care (1993) 4.04
An STS-based radiation hybrid map of the human genome. Genome Res (1997) 3.57
Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. Science (1998) 2.84
Effect of RF coil excitation on field inhomogeneity at ultra high fields: a field optimized TEM resonator. Magn Reson Imaging (2001) 2.84
Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci U S A (2000) 2.83
Variable and tissue-specific hormone resistance in heterotrimeric Gs protein alpha-subunit (Gsalpha) knockout mice is due to tissue-specific imprinting of the gsalpha gene. Proc Natl Acad Sci U S A (1998) 2.71
Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood (1968) 2.71
Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin. Genes Dev (1998) 2.37
The mouse c-abl locus: molecular cloning and characterization. Cell (1984) 2.33
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
Hemangioendothelial sarcoma of liver from chronic arsenic intoxication by Fowler's solution. Cancer (1968) 2.22
Adductor tenotomies in children with quadriplegic cerebral palsy: longer term follow-up. J Pediatr Orthop (2000) 2.21
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
Mice lacking major histocompatibility complex class I and class II molecules. Proc Natl Acad Sci U S A (1993) 2.18
Intensive cataract training: a novel approach. Eye (Lond) (2013) 2.17
N-cadherin regulates target specificity in the Drosophila visual system. Neuron (2001) 2.16
Filtration leukapheresis for granulocyte transfusion therapy. Clinical and laboratory studies. N Engl J Med (1975) 2.16
Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis (2008) 2.12
Amputation and adriamycin in primary osteosarcoma. N Engl J Med (1974) 2.04
In vivo cytokine gene expression in T cell subsets of the autoimmune MRL/Mp-lpr/lpr mouse. Eur J Immunol (1990) 2.00
NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res (1998) 2.00
Access to data: comparing AccessMed with Query by Review. J Am Med Inform Assoc (1996) 1.98
Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proc Natl Acad Sci U S A (2004) 1.98
An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Cancer Invest (1993) 1.94
Oncologists' reply: survival expectancy in acute lymphocytic leukemia. N Engl J Med (1972) 1.89
The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci U S A (1993) 1.86
Association of Epstein-Barr virus with thymic carcinoma. N Engl J Med (1985) 1.83
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood (1982) 1.79
Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code. EMBO J (2000) 1.78
Genomic structure and identification of novel mutations in usherin, the gene responsible for Usher syndrome type IIa. Am J Hum Genet (2000) 1.76
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med (1982) 1.75
Detection of mammary tumor virus env gene-like sequences in human breast cancer. Cancer Res (1995) 1.75
Elevated serum ribonuclease in patients with pancreatic cancer. Proc Natl Acad Sci U S A (1976) 1.74
Cloning and expression of a smooth muscle caldesmon. J Biol Chem (1989) 1.74
Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis (2003) 1.74
Adjuvant chemotherapy of breast cancer. Cancer (1979) 1.73
Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol (1998) 1.73
Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology (2000) 1.71
Quantification of arabinitol in serum by selected ion monitoring as a diagnostic technique in invasive candidiasis. J Clin Microbiol (1980) 1.70
Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. J Natl Cancer Inst (1996) 1.70
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood (1981) 1.68
Acute airway management in the critically ill child requiring transport. Can J Anaesth (1991) 1.63
An opportunistic infection with Corynebacterium pyogenes producing empyema. Am J Clin Pathol (1970) 1.62
Phosphorylation of the RNA polymerase II carboxy-terminal domain by the Bur1 cyclin-dependent kinase. Mol Cell Biol (2001) 1.61
Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem (1996) 1.61
Dielectric resonances and B(1) field inhomogeneity in UHFMRI: computational analysis and experimental findings. Magn Reson Imaging (2001) 1.60
Carbohydrate metabolism in lactic streptococci: fate of galactose supplied in free or disaccharide form. Appl Microbiol (1973) 1.57
A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol (1989) 1.56
Inpatient emergencies encountered by an infectious disease consultative service. Clin Infect Dis (1998) 1.56
Reovirus infection of cancer cells is not due to activated Ras pathway. Cancer Gene Ther (2008) 1.56
Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese. Eur J Neurol (2009) 1.54
Colonic polyps in an unselected population: prevalence, characteristics, and associations. Am J Gastroenterol (1994) 1.53
Paternal versus maternal transmission of a stimulatory G-protein alpha subunit knockout produces opposite effects on energy metabolism. J Clin Invest (2000) 1.51
Chemotherapy of acute lymphocytic leukemia of childhood. Cancer (1972) 1.50
Medical management of a large aortic thrombus in a young woman with essential thrombocythemia. Mayo Clin Proc (2001) 1.49
Attenuation of ischemic liver injury by monoclonal anti-endothelin antibody, AwETN40. J Am Coll Surg (1997) 1.47
Jugular venous bulb catheterization in infants and children. Crit Care Med (1989) 1.47
A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res (1999) 1.47
Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group. J Clin Oncol (1993) 1.46
Diffuse pulmonary malignant mesothelioma: response to doxorubicin and 5-azacytidine. Cancer (1978) 1.45
Fluorometric investigations of the interaction of polyene antibiotics with sterols. Biochemistry (1972) 1.42
Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis (1999) 1.42
The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg (1998) 1.42
Overdose with chloral hydrate: a pharmacological and therapeutic review. Med J Aust (1989) 1.42
Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer (1974) 1.42
Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients. Genes Chromosomes Cancer (2006) 1.41
Disease management. Decreasing cost and increasing patient satisfaction: the implementation of a cancer disease management program. Manag Care Interface (1999) 1.40
Theoretical model for an MRI radio frequency resonator. IEEE Trans Biomed Eng (2000) 1.40
The experience of nausea during sustained hyper-gravity flight with negligible angular velocity. Aviat Space Environ Med (2000) 1.40
UHG-based mutation screening in type 2B von Willebrand's disease: detection of a candidate mutation Ser547Phe. Thromb Haemost (1996) 1.39
Pediatric and neonatal critical care transport: a comparison of therapeutic interventions. Pediatr Emerg Care (1996) 1.39
Strategies to inhibit alloantibody production in alloprimed murine recipients of hematopoietic stem cell grafts. Am J Transplant (2015) 1.39
Performance of disabled persons on a chordic keyboard. Hum Factors (1986) 1.38
Cryoablation of ventricular tachycardia guided by return cycle mapping after entrainment. J Thorac Cardiovasc Surg (2001) 1.37
Identification of a proviral structure in human breast cancer. Cancer Res (2001) 1.37
Innexins: a family of invertebrate gap-junction proteins. Trends Genet (1998) 1.36
Biochemical and pharmacological studies with asparaginase in man. Cancer Res (1970) 1.34
DNA triple-helix specific intercalators as antigene enhancers: unfused aromatic cations. Biochemistry (1993) 1.34
Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation). Am J Obstet Gynecol (1983) 1.33
Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep (1974) 1.30
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
Lymphocyte function of Michigan dairy farmers exposed to polybrominated biphenyls. Science (1978) 1.30
A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients. Cancer (1973) 1.29
Isolation and functional comparison of bovine cardiac troponin T isoforms. J Biol Chem (1987) 1.29
Aromatase-deficient (ArKO) mice accumulate excess adipose tissue. J Steroid Biochem Mol Biol (2001) 1.28
A randomized, controlled clinical trial of a treatment for shoulder pain. Phys Ther (1997) 1.27